Lescol expanded indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA clears Novartis' Lescol and Lescol XL (fluvastatin) May 27 "to reduce the risk of undergoing coronary revascularization procedures" based on the Lescol Intervention Prevention Study (LIPS). Labeling states that "Lescol significantly reduced the risk of cardiac events by 22% (p=0.013, 181 patients in the Lescol group vs. 222 patients in the placebo group). Revascularization procedures comprised the majority of the initial cardiac events (143…in the Lescol group and 171 in the placebo group)." Lescol is the first statin to receive the indication. U.S. marketer Reliant plans to initiate a marketing campaign for both consumers and professionals in Jun
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.